Trial Profile

A Phase I Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy Study of Oral Monepantel in Individuals With Motor Neurone Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Monepantel (Primary)
Indications Amyotrophic lateral sclerosis; Motor neuron disease
Focus Adverse reactions; Pharmacokinetics
Acronyms MEND
Sponsors Neurizon Therapeutics; PharmAust

Most Recent Events

15 Oct 2024 According to the Neurizon Therapeutics media release, PharmAust has changed its name to Neurizon Therapeutics.
28 Feb 2024 Primary endpoint (Determination of Phase 2 Dose) has been met as per results published in the PharmAust Media Release.
28 Feb 2024 Results published in the PharmAust Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com